Lenvatinib enhances antitumor immunity of anti-PD-1 antibody

Area of Science:

• Oncology
• Immunology
• Pharmacology

Background:

• Lenvatinib is an oral multi-tyrosine kinase inhibitor targeting VEGF and FGF signaling pathways.
• Its antitumor efficacy is primarily attributed to the suppression of angiogenesis.
• Lenvatinib also demonstrates immunomodulatory effects, including T-cell activation and tumor-associated macrophage regulation.

Purpose of the Study:

• To review the antitumor mechanisms of lenvatinib.
• To summarize the effects of combining lenvatinib with anti-programmed cell death-1 (anti-PD-1) antibody therapy.
• To elucidate the synergistic antitumor activity observed in preclinical models.

Main Methods:

• Review of non-clinical evaluations in mouse tumor models.
• Analysis of lenvatinib's effects on angiogenesis and immune cells.
• Evaluation of combined lenvatinib and anti-PD-1 therapy outcomes.

Main Results:

• Lenvatinib inhibits angiogenesis, contributing to its antitumor efficacy.
• Lenvatinib activates effector T-cells and regulates tumor-associated macrophages.
• Combination therapy with lenvatinib and anti-PD-1 showed enhanced antitumor activity compared to monotherapy.

Conclusions:

• Lenvatinib possesses dual antitumor mechanisms: anti-angiogenesis and immunomodulation.
• Combination of lenvatinib with anti-PD-1 therapy offers a promising strategy for enhanced cancer treatment.
• Further research into lenvatinib-based immunotherapy combinations is warranted.